nature portfolio

Corresponding author(s):	Tim R. Blower
Last updated by author(s):	19th August 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

~ .				
51	ta:	t١	51	ICS

Fora	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🕱 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
x	A description of all covariates tested
x	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
x	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
×	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
×	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
,	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Sof	ftware and code

Software and code

Policy information about availability of computer code

Data collection

X-ray data was acquired using Diamond Light Source's "Generic Data Acquisition" (opengda.org) client to run the beamline, and iSpyB (R2.3) to visualise the data. Data were acquired on Diamond Light Source beamlines IO4 and I24.

Data analysis

Crystal data analysis:

Processing (indexing, integration, scaling) - XDS (Xia2-DIALS) v. Jan 10, 2022

Analysis of spacegroups - AIMLESS v8.0.011 Molecular replacement - PHASER v8.0.011

Initial Building and Refinement - BUCCANEER and REFMAC, respectively, v8.0.011

Refinement - PHENIX 1.19.2-4158

Building - Coot v0.9.8.7.1

Structural figures - PyMol v2.2.2

Image analysis:

Image Lab (Bio-Rad) v6.1

ImageJ v1.8.0

GraphPad Prism v10.2.0

Mass Spec analysis:		
MassLynx v4.1 (Waters)		
MaxEnt 3.1		

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The crystal structures of MenT1-p and MenT3 have been deposited in the Protein Data Bank under accession numbers 8RR5 and 8RR6, respectively. All other data needed to evaluate the conclusions in the paper are present in the paper and/or Supplementary Data.

Research involving human participants, their data, or biological material

Policy information about studies with <u>human participants or human data</u>. See also policy information about <u>sex, gender (identity/presentation), and sexual orientation</u> and <u>race, ethnicity and racism</u>.

Reporting on sex and gender	N/A
Reporting on race, ethnicity, or other socially relevant groupings	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one belov	w that is the best fit for your research. $!$	If you are not sure,	read the appropriate sections before making your selection.
x Life sciences	Behavioural & social sciences	Ecological, ev	volutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

No sample-size calculations were performed. For X-ray data, a minimum of 360° datasets were collected for both structures, and then merged with sufficient datasets to optimise resolution as judged within iSpyB and AIMLESS (Diamond Light Source). This provided sufficient data to solve the structures. For other experiments, duplicate or triplicate experiments were performed as standard for the techniques used.

Data exclusions

No data were excluded

Replication

All experimental findings described here were confirmed by repeating the experiments (see figure legends) and, when possible/applicable, by performing distinct experiments to support the same experimental finding. For the structural data, multiple rounds of refinement were performed and they converged to the same structures.

Randomization

Randomisation was not required. There were no covariates applicable within this study and therefore randomization was not needed.

Blinding

Blinding was not required, as it is not necessary for the techniques used.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		Met	Methods	
n/a	Involved in the study	n/a	Involved in the study	
	✗ Antibodies	×	ChIP-seq	
×	Eukaryotic cell lines	x	Flow cytometry	
x	Palaeontology and archaeology	×	MRI-based neuroimaging	
X	Animals and other organisms			
×	Clinical data			
×	Dual use research of concern			
×	Plants			
	'			

Antibodies

Antibodies used

Anti-GFP antibody, Anti-mouse IgG

Validation

Monoclonal anti-GFP (ThermoFisher, Catalog no. MA5-15256) was validated for western blot (https://www.thermofisher.com/antibody/product/GFP-Antibody-clone-GF28R-Monoclonal/MA5-15256). HRP-conjugate anti-mouse $\lg G (H + L)$ secondary antibody (Promega W4021).